NANegar Aghaei

Negar Aghaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Negar Aghaei has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell Therapy: A Review of Clinical Applications, Challenges, Emerging Technologies, and the Future Perspective

    by Zeinab Aliyari Serej, Behnaz Valipour, Abbas Ebrahimi Kalan, Negar Aghaei

    Cell therapy is rapidly emerging as a transformative approach in medicine, offering potential treatments for cure diseases that we cannot currently. Different cell types can be used in a variety of fields, including cancer immunotherapy, regenerative medicine, and treatment of autoimmune diseases. Cell therapy targets the cause of the disease rather than ...

  • Open Access

    Sleep and cognitive outcomes in multiple sclerosis; a systematic review

    by Behnam Golabi, Hadis Razmaray, Sepideh Seyedi-Sahebari, Heliya Bandehagh, Zahra Hakimzadeh, Ailin Khosroshahi, Seyedehyasmin Moghaddamziabari, Negar Aghaei, Sarvin Sanaie, Mahnaz Talebi, et al.

    Background: Multiple sclerosis (MS) is a disabling disease of the central nervous system. People living with MS often have co-existing sleep disorders and cognitive dysfunction. The objective of this study was to scrutinize the relationship between cognitive outcomes and sleep conditions in MS. Methods: This study followed the Joanna Briggs Institute’s (JBI) and PRISMA guidelines. PubMed, Scopus, Embase, and Web of Science databases were searched and original studies delineating the relationship between sleep status and cognitive findings in MS patients‌ were included. The risk of bias was assessed using the JBI critical appraisal tools. Results: In the final review, out of 1635 screened records, 35 studies with 5321 participants were included. Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and polysomnography were the most common assessment tools for evaluation of sleep condition, and cognitive evaluations were conducted using the tests including Paced Auditory Serial Addition Test (PASAT), California Verbal Learning Test (CVLT), Symbol Digit Modalities Test (SDMT) and Brief Visuospatial Memory Test (BVMT). Assessing the quality of studies showed no significant bias in most of the included articles. A link between sleep condition and cognitive abilities was suggested in the literature, especially with objective measurement of sleep condition; however, current evidence did not support a substantial association between self-reported sleep quality and processing speed and working memory in patients with MS. Discussion: Evidence proposes sleep is an independent factor associated with cognitive outcomes in MS. Given the limitations of the evidence such as the lack of well-designed prospective studies, these findings need to be interpreted with caution.


  • Shining a Light on Selenium: a Meta-analysis of Supplementation in Multiple Sclerosis

    by Mehrab Rahmani, Sina Pakkhesal, Saman Baharomid, Hanie Karimi, Reza Mosaddeghi-Heris, Mahnaz Talebi, Negar Aghaei, Alireza Rahimi-Mamaghani, Sarvin Sanaie, Amirreza Naseri

    Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease of the central nervous system. Selenium is a trace element with significant antioxidant activity. This study aimed to seek evidence concerning selenium supplementation in MS. A systematic search was performed on PubMed, Web of Science, Scopus, and Embase databases to identify the studies assessing the consumption rate, efficacy, and safety of selenium and selenium-containing supplementations in MS patients. The meta-analysis was performed using the Comprehensive Meta-Analysis and the risk of bias was evaluated using the Joanna Briggs Institute’s critical appraisal tools. A total of 9 studies were included, which consisted of six studies regarding the rate of selenium supplement consumption in MS patients, with a total sample size of 2381 patients. Based on the quantitative synthesis, 14.3% (95% CI, 12.8–16.0%; I2, 3.58%) of MS patients had current selenium supplements usage, and 11.3% (95% CI, 7.6–16.6%; I2, 81.40%) of patients had used selenium supplements previously. Although there is no evidence regarding supplementation with selenium alone, three RCT studies reported the safety of selenium-containing supplementation use in MS with improved inflammation and oxidative stress conditions. The findings of this study show that over 10% of patients with MS used selenium supplements, with no clinical significance supporting the benefits. There is a lack of evidence regarding the safety and efficacy of selenium supplements in MS patients. Due to the limited number of included studies and the lack of comprehensive and specific studies regarding selenium supplements in MS, the results must be interpreted with caution, and future clinical trials are required.